Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.

NCT07154238 | Enrolling By Invitation

• 2 other identifiers: NN9536-8412U1111-1314-6149
• Study Type: observational
• Target: 2,546
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.

Conditions

Obesity

Outcome Measures

Primary Outcomes (6)

• Description of characteristics, including clinical, demographic and physical characteristics, among individuals initiated on injectable semaglutide for weight management

  Patient Quantitative Segment Multi select from a defined list Single select from a defined list Numeric entry Open-ended type-in Patient Qualitative Segment Open-ended commentary

  At the time of survey response (Day 1)

• Description of the experience of individuals initiated on injectable semaglutide for weight management through personal perception of physical and mental health and self-reported QoL

  Patient Quantitative Segment 7-point Likert scale for agreement (where 1 indicates extremely dissatisfied and 7 indicates extremely satisfied) Single select from a defined list EQ-5D-5L Patient Qualitative Segment Open-ended commentary

  At the time of survey response (Day 1)

• Individual-reported change in BMI since initiation

  Patient Quantitative Segment Numeric entry (BMI calculated based on self-reported height and weight)

  At the time of survey response (Day 1)

• Individual-reported achievement of weight loss goal

  Patient Quantitative Segment Yes/No; percentage of weight loss goal achieved Patient Qualitative Segment Open-ended commentary

  At the time of survey response (Day 1)

• Individual-reported change in weight since initiation

  Patient Quantitative Segment Numeric entry in (kgs); percentage of weight change Patient Qualitative Segment Open-ended commentary

  At the time of survey response (Day 1)

• Individual-reported changes in daily life since initiation on injectable semaglutide

  Patient Qualitative Segment Open-ended commentary

  At the time of survey response (Day 1)

Secondary Outcomes (32)

• Treatment expectation of individuals initiated on injectable semaglutide of ability to achieve weight loss goal using injectable semaglutide

  At the time of survey response (Day 1)

• Expectation for length of time of treatment to desired result from date of initiation on injectable semaglutide at baseline

  At the time of survey response (Day 1)

• Expectation of individuals initiated on injectable semaglutide for weight management who believe they will have greater success in achieving their weight loss with the use of injectable semaglutide

  At the time of survey response (Day 1)

• Expected benefits of injectable semaglutide

  At the time of survey response (Day 1)

• Satisfaction with weight loss since initiation

  At the time of survey response (Day 1)

Study Arms (5)

Baseline

0 - 8 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is no more than eight weeks prior to the date that they complete the screener to participate in the study.

Other: No treatment given

End of Escalation Phase

16 - 24 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is at least 16 weeks but no more than 24 weeks prior to the date that they complete the screener to participate in the study.

Other: No treatment given

Weight Loss Phase

48 - 56 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is at least 48 weeks but no more than 56 weeks prior to the date that they complete the screener to participate in the study

Other: No treatment given

Stable Weight Phase

More than or equal to (≥) 68 weeks post-initiation, individuals who self-reported an initiation date as day, month and year combination that is at least 68 weeks prior to the date that they complete the screener to participate in the study.

Other: No treatment given

Healthcare Providers (HCP)s

HCPs will be recruited from an opt-in panel available in each country which includes the practitioners representing different settings of obesity care. Qualified HCPs will be invited to participate in a one-on-one IDI with a moderator from each of the participating countries.

Other: No treatment given

Interventions

No treatment given OTHER

No treatment given

Baseline; End of Escalation Phase; Healthcare Providers (HCP)s; Stable Weight Phase; Weight Loss Phase

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This study will collect quantitative and qualitative data from individuals treated with injectable semaglutide for weight management in real-world settings. The study will include two groups of participants: 1. Individuals who belong to or are recruited to an opt-in panel in the countries of interest and who have initiated injectable semaglutide for weight management. They will be classified according to the time when they first initiated treatment with injectable semaglutide for weight management. 2. HCPs who prescribe injectable semaglutide for weight management will be recruited from an existing opt-in panel in the countries of interest.

You may qualify if:

• Electronically provided consent obtained before any study-related activities can be completed.
• Age above or equal to 18 years at the time of providing informed consent.
• Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain.
• Have been prescribed and initiated injectable semaglutide for weight management prior to study screening.
• Electronically provided consent obtained before any study-related activities can be completed.
• Practice in a participating country: Australia, Germany, UAE, and Spain.
• See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month.
• Treat at least 10 adult patients per month for weight management.
• Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs).
• Prescribe injectable semaglutide for weight management.
• Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others.

You may not qualify if:

• Unwillingness or language barriers precluding adequate understanding or cooperation.
• Is currently or planning to become pregnant in next six months.
• Is taking injectable semaglutide for Type 2 diabetes management only.
• Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview.
• Unwillingness or language barriers precluding adequate understanding or cooperation.
• Only treats patients under 18 years of age.

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Novo Nordisk Investigational Site

Bad Oeynhausen, 32545, Germany

Location

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Clinical Transparency (dept. 2834)

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 26, 2025
• First Posted: September 4, 2025
• Study Start: September 26, 2025
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): September 30, 2026
• Last Updated: November 25, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will share

Locations

DE (1)